Page 12 - ஸ்பெக்ட்ரம் மருந்துகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GT Biopharma Appoints Two New Independent Directors

GT Biopharma Appoints Two New Independent Directors News provided by Share this article Share this article BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company s proprietary NK cell engager (TriKE™) technology platform today announced the appointment of Michael Breen and Rajesh Shrotriya MD to the Company s Board of Directors (the Board ), effective immediately. Mr. Breen and Dr. Shrotriya bring strong operational skills, deep understanding of drug development and significant leadership experience to the Board. We are pleased to welcome Michael and Rajesh to the GT Biopharma Board, said Anthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma. As part of our transition to NASDAQ we have now reconstituted our board. Michael and Rajesh bring unique skills and expertise, as well as significant experience serving on boards of directors of

Anthony cataldoBeverly hillsRajesh shrotriyaMichael breenAndrew barwickiNeotherapeutics incBristol myers squibb companySupergen incEntertainment division of bank insinger de beaufortLuxembourg stock exchangeSpectrum pharmaceuticals incInsinger de beaufort holdingsClinical researchParibas groupUniversity of minnesotaPrnewswire gt biopharma inc

Hanmi Pharmaceutical expects U S FDA approval for 2 new drugs

LAPSTriple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion Efpeglenatide met the primary endpoint for global Phase 3 Striving for developing rare diseases such as a once-a-month drug for short-bowel syndrome SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. What will be Hanmi s 2021 R&D strategy on new drugs Se Chang Kwon, the CEO of Hanmi Pharmaceutical Co., Ltd., is presenting the vision and strategy of Hanmi Pharmaceutical Co., Ltd. in 2021 at the 39th JP Morgan Conference.

Chang kwonCo ltdStandigm incGenentech incAthenex incSpectrum pharmaceuticals incTherapeutics incHanmi pharmaceutical co ltdPhanes therapeutics incInnovent biologics incSpectrum pharmaceuticalsFast trackPhanes therapeuticsBeijing hanmiInnovent biologicsHanmi pharmaceutical

Osteosarcoma Market Share Analysis, Future Growth, Size Estimation, Trends Analysis, COVID-19 Impact and Industry Dynamics By 2025

Osteosarcoma Market Share Analysis, Future Growth, Size Estimation, Trends Analysis, COVID-19 Impact and Industry Dynamics By 2025
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United kingdomAsia pacificAkash anandResearch reportBellicum pharmaceuticalsResearch reportsAdvaxis incOsteosarcoma market researchMarket research futureMarket researchResearch newswireSpectrum pharmaceuticals incSee campaignConsulting servicesHikma pharmaceuticalsFree sample copy

Apic Bio Announces the Appointment of Stephen Hoffman, MD, PhD, as Board Chair

Posted on 387 Apic Bio Inc. today announced the appointment of Stephen Hoffman, MD, PhD, as Chairman of the Board. Dr. Hoffman has a distinguished career in life sciences spanning decades. Most recently he was the chief executive officer of Aerpio Pharmaceuticals, Inc., from 2017 to 2019 and has served as senior advisor to PDL BioPharma, Inc., since 2014. Prior to that, he was a managing director at Skyline Ventures, a venture capital firm, from 2007 until 2014. Apic’s Co-founder and Chief Executive Officer, John Reilly, said, “We are thrilled to have Stephen head our board as we continue to advance our programs in SOD1 ALS and Alpha-1. Stephen’s scientific and medical background along with his track record in business development and experience with gene therapy companies, will be particularly helpful. We look forward to working with Stephen and the rest of the board as we continue to advance our pipeline and lev

United statesDavid rosenJohn reillyApic bioStephen hoffmanSomatogen incBaxter international incSpectrum pharmaceuticals incAcelrx pharmaceuticals incApic bio incUniversity of colorado school medicineInvestment fundAerpio pharmaceuticals incAllos therapeutics incGenocea biosciences incDicerna pharmaceuticals inc

88 Biggest Movers From Yesterday

88 Biggest Movers From Yesterday Benzinga 12/24/2020 Gainers Ocugen, Inc. (NASDAQ: OCGN) shares climbed 222.9% to close at $2.60 on Wednesday after the company announced it will convene its Meeting of Stockholders on Dec. 23 to modify a proposal, decreasing the proposed aggregate number of shares of common stock that the Company would be authorized to issue. Ocugen shares jumped around 174% on Tuesday after the company and Bharat Biotech announced plans to co-develop a whole-virion inactivated COVID-19 vaccine candidate. Jaguar Health, Inc. (NASDAQ: JAGX) jumped 170.3% to close at $1.07 after the company signed an agreement with a secured lender involving the $6 million sale of royalty interest in Mytesi royalties.

Li zhiUnited statesNeurocrine biosciencesScopus biopharmaDan fairfaxDonna franatoAvinger incQuantumscape corporationCyclacel pharmaceuticals incMd incScopus biopharma incJaguar health incFujitsu technologyGritstone oncology incTriterras incGainersocugen inc